Imatinib dry powder inhalation (Aerovate Therapeutics)

伊马替尼干粉吸入剂 (Aerovate Therapeutics)

Report date: 2025/05/08 10:52:50

Base Information

Drug NameImatinib dry powder inhalation (Aerovate Therapeutics)
Drug Alias NameAV-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsBcr-Abl tyrosine kinase inhibitorsStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptorBcr-Abl tyrosine kinasePlatelet-derived growth factor receptor
Therapy Area/IndicationsPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesJade Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJade Biosciences IncIqvia Rds (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsPulmonary Arterial Hypertension

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG